CD8-Positive T-Lymphocytes
"CD8-Positive T-Lymphocytes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
| Descriptor ID |
D018414
|
| MeSH Number(s) |
A11.118.637.555.567.569.220 A15.145.229.637.555.567.569.220 A15.382.490.555.567.569.220
|
| Concept/Terms |
CD8-Positive T-Lymphocytes- CD8-Positive T-Lymphocytes
- CD8 Positive T Lymphocytes
- CD8-Positive T-Lymphocyte
- T-Lymphocyte, CD8-Positive
- T-Lymphocytes, CD8-Positive
- T8 Lymphocytes
- Lymphocyte, T8
- Lymphocytes, T8
- T8 Lymphocyte
- T8 Cells
- Cell, T8
- Cells, T8
- T8 Cell
- CD8-Positive Lymphocytes
- CD8 Positive Lymphocytes
- CD8-Positive Lymphocyte
- Lymphocyte, CD8-Positive
- Lymphocytes, CD8-Positive
Suppressor T-Lymphocytes, CD8-Positive- Suppressor T-Lymphocytes, CD8-Positive
- CD8-Positive Suppressor T-Lymphocyte
- CD8-Positive Suppressor T-Lymphocytes
- Suppressor T Lymphocytes, CD8 Positive
- Suppressor T-Lymphocyte, CD8-Positive
- T-Lymphocyte, CD8-Positive Suppressor
- T-Lymphocytes, CD8-Positive Suppressor
- Suppressor T-Cells, CD8-Positive
- CD8-Positive Suppressor T-Cell
- CD8-Positive Suppressor T-Cells
- Suppressor T Cells, CD8 Positive
- Suppressor T-Cell, CD8-Positive
- T-Cell, CD8-Positive Suppressor
- T-Cells, CD8-Positive Suppressor
|
Below are MeSH descriptors whose meaning is more general than "CD8-Positive T-Lymphocytes".
Below are MeSH descriptors whose meaning is more specific than "CD8-Positive T-Lymphocytes".
This graph shows the total number of publications written about "CD8-Positive T-Lymphocytes" by people in this website by year, and whether "CD8-Positive T-Lymphocytes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 8 | 10 |
| 1996 | 3 | 3 | 6 |
| 1997 | 3 | 4 | 7 |
| 1998 | 4 | 7 | 11 |
| 1999 | 5 | 5 | 10 |
| 2000 | 5 | 10 | 15 |
| 2001 | 4 | 4 | 8 |
| 2002 | 10 | 6 | 16 |
| 2003 | 11 | 11 | 22 |
| 2004 | 9 | 10 | 19 |
| 2005 | 17 | 8 | 25 |
| 2006 | 16 | 9 | 25 |
| 2007 | 14 | 16 | 30 |
| 2008 | 13 | 11 | 24 |
| 2009 | 18 | 10 | 28 |
| 2010 | 9 | 15 | 24 |
| 2011 | 16 | 9 | 25 |
| 2012 | 13 | 14 | 27 |
| 2013 | 17 | 9 | 26 |
| 2014 | 16 | 19 | 35 |
| 2015 | 10 | 8 | 18 |
| 2016 | 12 | 12 | 24 |
| 2017 | 19 | 15 | 34 |
| 2018 | 14 | 20 | 34 |
| 2019 | 24 | 25 | 49 |
| 2020 | 16 | 28 | 44 |
| 2021 | 19 | 33 | 52 |
| 2022 | 13 | 31 | 44 |
| 2023 | 11 | 29 | 40 |
| 2024 | 18 | 25 | 43 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD8-Positive T-Lymphocytes" by people in Profiles.
-
Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas. Neuro Oncol. 2024 Dec 05; 26(12):2239-2255.
-
Anti-CD8/IL-15 (N72D)/sushi fusion protein: A promising strategy for improvement of cancer immunotherapy. Cytokine. 2025 Jan; 185:156822.
-
Tumor Expression of CD83 Reduces Glioma Progression and Is Associated with Reduced Immunosuppression. Cancer Res Commun. 2024 Dec 01; 4(12):3209-3223.
-
Engineering immunity: bacterial delivery of cancer neoantigen vaccines. Trends Immunol. 2024 Dec; 45(12):931-933.
-
CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: A Review. JCO Precis Oncol. 2024 Oct; 8:e2400183.
-
IL-2/anti-IL-2 antibody complexes augment immune responses to therapeutic cancer vaccines. Proc Natl Acad Sci U S A. 2024 Nov 26; 121(48):e2322356121.
-
CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8+ T cells. Gut. 2024 Nov 11; 73(12):1984-1998.
-
Longitudinal analysis of the gut microbiota during anti-PD-1 therapy reveals stable microbial features of response in melanoma patients. Cell Host Microbe. 2024 Nov 13; 32(11):2004-2018.e9.
-
Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy. Cell Rep. 2024 Nov 26; 43(11):114875.
-
Histone lactylation drives CD8+ T cell metabolism and function. Nat Immunol. 2024 Nov; 25(11):2140-2151.